{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T14:17:16Z","timestamp":1788358636011,"version":"build-2803163510"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background\/aim:<\/jats:bold> Tenofovir amibufenamide (TMF) has shown potent antiviral efficacy in randomized clinical studies. This study aimed to reveal the effectiveness and safety of tenofovir amibufenamide in the real world and compared tenofovir amibufenamide to tenofovir alafenamide (TAF) in patients with chronic hepatitis B (CHB).<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> In this retrospective study, tenofovir amibufenamide-treated chronic hepatitis B patients were divided into treatment-naive (TN) and treatment-experienced (TE) groups. Furthermore, tenofovir alafenamide-treated patients were enrolled using the propensity score matching method (PSM). We assessed the virological response (VR, HBV DNA &amp;lt; 100\u00a0IU\/mL) rate, renal function, and blood lipid changes during 24\u00a0weeks of treatment.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Virologic response rates at week 24 were 93% (50\/54) in the treatment-naive group and 95% (61\/64) in the treatment-experienced group. The ratios of alanine transaminase (ALT) normalization were 89% (25\/28) in the treatment-naive group and 71% (10\/14) in the treatment-experienced group (<jats:italic>p<\/jats:italic> = 0.306). Additionally, serum creatinine decreased in both the treatment-naive and treatment-experienced groups, (\u22124.44 \u00b1 13.55\u00a0\u03bcmol\/L <jats:italic>vs.<\/jats:italic> \u22124.14 \u00b1 9.33\u00a0\u03bcmol\/L, <jats:italic>p<\/jats:italic> = 0.886), estimated glomerular filtration rate (eGFR) increased (7.01 \u00b1 12.49\u00a0ml\/min\/1.73\u00a0m<jats:sup>2<\/jats:sup><jats:italic>vs.<\/jats:italic> 5.50 \u00b1 8.16\u00a0ml\/min\/1.73\u00a0m<jats:sup>2<\/jats:sup>, <jats:italic>p<\/jats:italic> = 0.430), and low-density lipoprotein cholesterol (LDL-C) levels increased (0.09 \u00b1 0.71\u00a0mmol\/L <jats:italic>vs.<\/jats:italic> 0.27 \u00b1 0.68\u00a0mmol\/L, <jats:italic>p<\/jats:italic> = 0.152), whereas total cholesterol\/high-density lipoprotein cholesterol (TC\/HDL-C) levels decreased continuously from 3.26 \u00b1 1.05 to 2.49 \u00b1 0.72 in the treatment-naive group and from 3.31 \u00b1 0.99 to 2.88 \u00b1 0.77 in the treatment-experienced group. Using propensity score matching, we further compared virologic response rates between the tenofovir amibufenamide and tenofovir alafenamide cohorts. Virologic response rates in treatment-naive patients were higher in the tenofovir amibufenamide cohort [92% (35\/38) <jats:italic>vs.<\/jats:italic> 74% (28\/38), <jats:italic>p<\/jats:italic> = 0.033]. Virologic response rates in treatment-experienced patients showed no statistical difference between the tenofovir amibufenamide and tenofovir alafenamide cohorts.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Tenofovir amibufenamide had profound antiviral effectiveness and no adverse effects on renal function or blood lipids. Additionally, tenofovir amibufenamide was more efficient than tenofovir alafenamide in inhibiting viral replication, which needs to be demonstrated in future studies.<\/jats:p>","DOI":"10.3389\/fphar.2023.1165990","type":"journal-article","created":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T04:58:06Z","timestamp":1685595486000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":21,"title":["Effectiveness and safety of tenofovir amibufenamide and its comparison with tenofovir alafenamide in patients with chronic hepatitis B: results from a retrospective real-world study"],"prefix":"10.3389","volume":"14","author":[{"given":"Lanqing","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fada","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongmei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menglan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yachao","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enqiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,6,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.jhep.2017.11.039","article-title":"96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for Hepatitis B virus infection","volume":"68","author":"Agarwal","year":"2018","journal-title":"J. Hepatol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.jhep.2014.10.035","article-title":"Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic Hepatitis B infection","volume":"62","author":"Agarwal","year":"2015","journal-title":"J. Hepatol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.cgh.2021.04.045","article-title":"Tenofovir alafenamide for drug-resistant hepatitis B: A randomized trial for switching from tenofovir disoproxil fumarate","volume":"20","author":"Byun","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.3892\/etm.2021.10760","article-title":"Efficacy and safety of tenofovir alafenamide fumarate in nucleoside analogue treatment-na\u00efve patients with chronic Hepatitis B","volume":"22","author":"Chen","year":"2021","journal-title":"Exp. Ther. Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.cgh.2020.05.008","article-title":"Effects of tenofovir vs entecavir on risk of hepatocellular carcinoma in patients with chronic HBV infection: A systematic review and meta-analysis","volume":"19","author":"Choi","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1111\/jvh.13500","article-title":"Effectiveness and renal safety of tenofovir alafenamide fumarate among chronic hepatitis B patients: Real-world study","volume":"28","author":"Farag","year":"2021","journal-title":"J. Viral Hepat."},{"key":"B7","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/S2468-1253(22)00124-8","article-title":"Global, regional, and national burden of Hepatitis B, 1990-2019: A systematic analysis for the global burden of disease study 2019","volume":"7","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1002\/hep.24318","article-title":"Virological breakthrough and resistance in patients with chronic Hepatitis B receiving nucleos(t)ide analogues in clinical practice","volume":"53","author":"Hongthanakorn","year":"2011","journal-title":"Hepatology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1136\/gutjnl-2013-305517","article-title":"HBsAg seroclearance after nucleoside analogue therapy in patients with chronic Hepatitis B: Clinical outcomes and durability","volume":"63","author":"Kim","year":"2014","journal-title":"Gut"},{"key":"B10","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1002\/hep.28916","article-title":"Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment","volume":"66","author":"Kim","year":"2017","journal-title":"Hepatology"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1111\/liv.15261","article-title":"Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in treatment-na\u00efve chronic Hepatitis B","volume":"42","author":"Lim","year":"2022","journal-title":"Liver Int."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1111\/apt.16611","article-title":"Randomised clinical trial: 48 weeks of treatment with tenofovir amibufenamide versus tenofovir disoproxil fumarate for patients with chronic Hepatitis B","volume":"54","author":"Liu","year":"2021","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1111\/liv.14155","article-title":"Ten-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic Hepatitis B virus infection","volume":"39","author":"Marcellin","year":"2019","journal-title":"Liver Int."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e0251552","DOI":"10.1371\/journal.pone.0251552","article-title":"Antiviral kinetics of tenofovir alafenamide and tenofovir disoproxil fumarate over 24 weeks in women of childbearing potential with chronic HBV","volume":"16","author":"Pan","year":"2021","journal-title":"PLoS One"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1177\/2047487319862401","article-title":"Total cholesterol\/HDL-cholesterol ratio discordance with LDL-cholesterol and non-HDL-cholesterol and incidence of atherosclerotic cardiovascular disease in primary prevention: The ARIC study","volume":"27","author":"Quispe","year":"2020","journal-title":"Eur. J. Prev. Cardiol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-pacific clinical practice guidelines on the management of Hepatitis B: A 2015 update","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatol. Int."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.2165\/00003495-200969080-00005","article-title":"Entecavir: A review of its use in chronic Hepatitis B","volume":"69","author":"Scott","year":"2009","journal-title":"B. Drugs."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1111\/jgh.12476","article-title":"Changes of HBsAg and HBV DNA levels in Chinese chronic Hepatitis B patients after 5 years of entecavir treatment","volume":"29","author":"Seto","year":"2014","journal-title":"J. Gastroenterol. Hepatol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1111\/j.1478-3231.2010.02384.x","article-title":"Chronic Hepatitis B: Peginterferon or nucleos(t)ide analogues?","volume":"31","author":"Sonneveld","year":"2011","journal-title":"Liver Int."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1016\/j.cgh.2020.03.001","article-title":"Persistent low level of hepatitis B virus promotes fibrosis progression during therapy","volume":"18","author":"Sun","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1038\/s41440-019-0251-5","article-title":"Associations of non-high-density lipoprotein cholesterol, triglycerides and the total cholesterol\/HDL-c ratio with arterial stiffness independent of low-density lipoprotein cholesterol in a Chinese population","volume":"42","author":"Wen","year":"2019","journal-title":"Hypertens. Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"411","DOI":"10.3350\/cmh.2020.0049","article-title":"Comparison of clinical practice guidelines for the management of chronic Hepatitis B: When to start, when to change, and when to stop","volume":"26","author":"Yim","year":"2020","journal-title":"Clin. Mol. Hepatol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/apt.16196","article-title":"Randomised clinical trial: Safety, efficacy and pharmacokinetics of HS-10234 versus tenofovir for the treatment of chronic Hepatitis B infection","volume":"53","author":"Zhang","year":"2021","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B24","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/S2468-1253(18)30308-X","article-title":"Spontaneous loss of surface antigen among adults living with chronic Hepatitis B virus infection: A systematic review and pooled meta-analyses","volume":"4","author":"Zhou","year":"2019","journal-title":"Lancet Gastroenterol. Hepatol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1165990\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T04:58:08Z","timestamp":1685595488000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1165990\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,1]]},"references-count":24,"alternative-id":["10.3389\/fphar.2023.1165990"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1165990","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,1]]},"article-number":"1165990"}}